MedTrace Logo

De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx

NCT05600842 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 111

Last updated 2026-05-05

No results posted yet for this study

Summary

This is a single-arm, observational registry study determining the effects of reduced radiation dose in select patients with human papillomavirus (HPV) positive oropharyngeal cancer.

Conditions

  • HPV Positive Oropharyngeal Squamous Cell Carcinoma

Interventions

RADIATION

Intensity-Modulated Radiation Therapy (IMRT)

IMRT will be given in 30 daily fractions at 2 Gy per fraction (60 Gy total) beginning Day 1; Six fractions will be delivered per week. High risk patients will receive induction chemotherapy with 2 cycles of carboplatin and paclitaxel.

Sponsors & Collaborators

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Eric Chen, MD · Chao Family Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-03
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05600842 on ClinicalTrials.gov